College of Medicine
Chapman Lab
Led by Eli Chapman · Pharmacology and Therapeutics
What we study
The Chapman Lab studies small molecules that control protein folding and stress responses in cells. They develop compounds to target chaperones like HSP70, HSP60/10, and NRF2 for potential cancer treatments and antibiotics.
What working here is like
- Wet lab
- Bacteria & microbes
- Projects
- 3
- Papers
- 4
Current projects
Isoform selective HSP70 inhibitors
Developing compounds to selectively target HSP70 isoforms for cancer treatment.
GroEL/ES inhibitors as antibiotics
Optimizing compounds to target bacterial chaperones for MRSA treatment.
Show 1 more projectsShow fewer
NRF2 activators and inhibitors
Discovering compounds to activate or block NRF2 for chemoprevention and cancer therapy.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- NRF2-mediated ferroptosis suppression defines a cancer-specific vulnerability in tumors
2026 · Redox Biology
Shows that removing NRF2 protein kills cancer cells in mice without harming normal tissues.
- Development of Isoform-Selective GRP78 Inhibitors from a Direct-to-Biology Strategy
2026 · Journal of Medicinal Chemistry
Develops a drug that targets GRP78 protein in cancer cells but not normal cells.
Show 2 more papersShow fewer
- Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma
2025 · Biomolecules
Tests whether UPR-inducing drugs can treat skin cancer by affecting CTCL cells' survival and immune response.
- CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth
2025 · Molecular Carcinogenesis
Finds that CYP4F11, a protein controlled by NRF2, helps liver cancer cells grow.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Eli Chapman hasn't set up this page yet. You can also look them up in the UF directory (search “Eli Chapman”).